Representative study BG profiles from the forearm and the fingertip of six patients with diabetes. Representative study BG profiles from the forearm and.

Slides:



Advertisements
Similar presentations
Abstract Background: As part of a study to evaluate the accuracy of the GlucoWatch ® G2 TM Biographer and the Continuous Glucose Monitoring System (CGMS.
Advertisements

Identify the risk factors, diagnosis and prevalence of diabetes in the United States. Describe the function of the pancreas, the intestines and liver.
Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.
Best offer from Medtek.  Multiple blood chemistry testing  One-step testing  Results in two minutes or less  Automatic calibration with inserted MEMo-Chip.
UR Medicine at Ridgeland Road Clinical Trials Central Laboratory
Protocol for the management of adult patients with DKA
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
The Research Question Does self monitoring of blood glucose (SMBG) in patients with non-insulin treated type 2 diabetes improve glycemia or quality of.
The risk of DR progression as related to mean HbA1c during DCCT
Protocol for management of adult patients with DKA or HHS
Protocol for the management of adult patients with HHS
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.
The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.
Modern Advances in Glucose Monitoring
Protocol for the management of adult patients with HHS
Hypoglycemia: The Most Common Barrier to Effective Diabetes Management
Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.
Protocol for the management of adult patients with DKA
Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.
Demonstration of the cascade of clinical events and metabolic changes that contribute sequentially to progressive clinical deterioration and development.
Effect of metformin on glycemic control, insulin secretion, and insulin sensitivity in T2D. Effect of metformin on glycemic control, insulin secretion,
Disorders of glycemia: etiologic types and stages
The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.
Results for HbA1c (A), severe or BG-confirmed symptomatic hypoglycemia (B), change in body weight (C), daily total insulin dose (D), FPG (E), and nine-point.
Glucose, insulin, and AGE levels during an OGC before and after RT
Study protocol. Study protocol. Fourteen patients had research renal biopsies, and 17 patients with macroalbuminuria had renal biopsies for clinical reasons.
The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.
The concept of immortal time bias is depicted schematically using the cohort study from the Taiwanese National Health Insurance data during 2000–2007:
Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.
Comparison of the regression lines for AIRarg (the acute insulin response to intravenous arginine over 2–5 min after injection) and AIRargMAX (the response.
Forefoot peak plantar pressure in diabetic patients without and with mild, moderate, and severe peripheral neuropathy. *Severe and moderate neuropathy.
A: The correlation between the GIR and FGU, each measured during the last 40 min of the euglycemic insulin clamp. A: The correlation between the GIR and.
The underlying physiological basis of the HOMA model.
Insulin sensitivity in athletes and sedentary normal-weight and obese, young, and old individuals. Insulin sensitivity in athletes and sedentary normal-weight.
A: Chemical structure of pterosin A
Glucose control performance (by CGM) characterized by median and interquartile range cumulative % time in glucose range (A), overall glucose (B), and insulin.
Adoptive transfer of purified activated G9Cα−/−
GLP-1 and gastrin combination therapy induces immunoregulatory cell activity in NOD mice. GLP-1 and gastrin combination therapy induces immunoregulatory.
Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.
Fig. 5 In vivo evaluation of F-insulin for treatment of type 1 diabetic minipig. In vivo evaluation of F-insulin for treatment of type 1 diabetic minipig.
Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.
(A) Oral glucose tolerance test (OGTT) glucose and (C) natural logarithm of insulin responses over time with SEM bars comparing the first tertile to the.
Glucose sensitivity of first-phase (σ1, dynamic secretion component) and second-phase (σ2, static secretion component) insulin secretion among NGT, IFG,
Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.
Glycemic control and body weight over 52 weeks.
Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.
Case report: male 63 years old with documented stenosis of the internal cerebral artery, diabetes duration 12 years, and treatment with 22 IU insulin glargine.
Median (interquartile range) of sensor glucose (A) and insulin delivery (B) during closed-loop (solid red line and red shaded area) and control period.
Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.
RBP4 and glucose metabolism.
Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.
(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.
Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.
(A) Changes in BG level during REST, ST-EX and BI-EX trials in the combined (ALL) group. * and ** indicate the presence of significant differences (p
Distribution of daily frequency of BGM
Disorders of glycemia: etiologic types and stages
Spearman rank order correlation between suppression of hepatic glucose production with low insulin infusion and 30-min change in glucose response in women.
Postoperative blood glucose levels and total insulin requirement.
A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.
Risk of mortality in patients with diabetes and ESRD
Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.
The ADA research program supports research across the broad spectrum of diabetes types and research topic areas (proportions of 2011 allocations in dollars).
Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.
Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.
Cumulative mean numbers of confirmed (plasma glucose ≤3
Insulin secretion (hyperglycemic clamp) (A), insulin sensitivity (hyperinsulinemic-euglycemic clamp) (B), and glucose disposition index (GDI) (C) in adolescents.
Presentation transcript:

Representative study BG profiles from the forearm and the fingertip of six patients with diabetes. Representative study BG profiles from the forearm and the fingertip of six patients with diabetes. Changes in BG were induced with 75 g oral glucose (t = 0) and by intravenous insulin injection. BG was analyzed using three different BG monitors as well as a clinical chemistry laboratory (CC-lab) method. Karsten Jungheim, and Theodor Koschinsky Dia Care 2002;25:956-960 ©2002 by American Diabetes Association

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.